Karyopharm Therapeutics To Present Results Of Phase 3 SENTRY Trial In Late-Breaking Oral Presentation Titled: Selinexor Plus Ruxolitinib In JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY Trial At 2026 ASCO Annual Meeting

뉴스 본문을 불러오고 있어요.

Karyopharm Therapeutics To Present Results Of Phase 3 SENTRY Trial In Late-Breaking Oral Presentation Titled: Selinexor Plus Ruxolitinib In JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY Trial At 2026 ASCO Annual Meeting | 웨이프 WAPE

Karyopharm Therapeutics To Present Results Of Phase 3 SENTRY Trial In Late-Breaking Oral Presentation Titled: Selinexor Plus Ruxolitinib In JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY Trial At 2026 ASCO Annual Meeting

기사 요약

관련 종목

댓글 —